Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial
Zinman, Bernard × Fulcher, Greg Rao, Paturi V Thomas, Nihal Endahl, Lars A Johansen, Thue Lindh, Rebecka Lewin, Andrew Rosenstock, Julio Pinget, Michel Mathieu, Chantal #
The Lancet Publishing Group
The Lancet vol:377 issue:9769 pages:924-31
Insulin degludec is a new basal insulin that forms soluble multihexamer assemblies after subcutaneous injection, resulting in an ultra-long action profile. This study aimed to assess efficacy and safety of insulin degludec injected once a day or three times a week compared with insulin glargine once a day in insulin-naive people with type 2 diabetes, who were inadequately controlled with oral antidiabetic drugs.